Published in Circ Res on December 01, 1997
Action potential and contractility changes in [Na(+)](i) overloaded cardiac myocytes: a simulation study. Biophys J (2000) 3.26
Regulation of cardiac excitation-contraction coupling by action potential repolarization: role of the transient outward potassium current (I(to)). J Physiol (2003) 2.19
MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca²⁺ overload and cell death. J Clin Invest (2012) 1.90
Na-Ca exchange and the trigger for sarcoplasmic reticulum Ca release: studies in adult rabbit ventricular myocytes. Biophys J (1998) 1.86
Altered intracellular Ca2+ handling in heart failure. J Clin Invest (2005) 1.70
Na(+)/K)+)-ATPase α2-isoform preferentially modulates Ca2(+) transients and sarcoplasmic reticulum Ca2(+) release in cardiac myocytes. Cardiovasc Res (2012) 1.36
Role of sodium-calcium exchanger in modulating the action potential of ventricular myocytes from normal and failing hearts. Circ Res (2003) 1.35
Modulation of the Ca(2+)-induced Ca(2+) release cascade by beta-adrenergic stimulation in rat ventricular myocytes. J Physiol (2001) 1.26
T-type Ca2+ current as a trigger for Ca2+ release from the sarcoplasmic reticulum in guinea-pig ventricular myocytes. J Physiol (1998) 1.22
Quantification of calcium entry at the T-tubules and surface membrane in rat ventricular myocytes. Biophys J (2005) 1.19
Mechanisms underlying the frequency dependence of contraction and [Ca(2+)](i) transients in mouse ventricular myocytes. J Physiol (2002) 1.17
There goes the neighborhood: pathological alterations in T-tubule morphology and consequences for cardiomyocyte Ca2+ handling. J Biomed Biotechnol (2010) 1.17
Alterations in action potential profile enhance excitation-contraction coupling in rat cardiac myocytes. J Physiol (2001) 1.17
Activation of reverse Na+-Ca2+ exchange by the Na+ current augments the cardiac Ca2+ transient: evidence from NCX knockout mice. J Physiol (2010) 1.16
Impact of sarcoplasmic reticulum calcium release on calcium dynamics and action potential morphology in human atrial myocytes: a computational study. PLoS Comput Biol (2011) 1.15
Na⁺ transport in the normal and failing heart - remember the balance. J Mol Cell Cardiol (2013) 1.14
Heart failure -- a challenge to our current concepts of excitation-contraction coupling. J Physiol (2003) 1.14
Contribution of the Na+/Ca2+ exchanger to rapid Ca2+ release in cardiomyocytes. Biophys J (2006) 1.10
Dysregulated sarcoplasmic reticulum calcium release: potential pharmacological target in cardiac disease. Pharmacol Ther (2008) 1.09
Local regulation of the threshold for calcium sparks in rat ventricular myocytes: role of sodium-calcium exchange. J Physiol (1999) 1.06
Spatial characteristics of sarcoplasmic reticulum Ca2+ release events triggered by L-type Ca2+ current and Na+ current in guinea-pig cardiac myocytes. J Physiol (2002) 1.02
Sodium-calcium exchange is essential for effective triggering of calcium release in mouse heart. Biophys J (2010) 1.01
Allosteric activation of Na+-Ca2+ exchange by L-type Ca2+ current augments the trigger flux for SR Ca2+ release in ventricular myocytes. Biophys J (2008) 1.01
Voltage-dependent Ca2+ release from the SR of feline ventricular myocytes is explained by Ca2+-induced Ca2+ release. J Physiol (2000) 1.00
Na+ currents are required for efficient excitation-contraction coupling in rabbit ventricular myocytes: a possible contribution of neuronal Na+ channels. J Physiol (2010) 0.97
Variability in couplon size in rabbit ventricular myocytes. Biophys J (2005) 0.97
Three-dimensional distribution of cardiac Na+-Ca2+ exchanger and ryanodine receptor during development. Biophys J (2007) 0.95
Junctional cleft [Ca²⁺]i measurements using novel cleft-targeted Ca²⁺ sensors. Circ Res (2014) 0.93
Can the sodium-calcium exchanger initiate or suppress calcium sparks in cardiac myocytes? Biophys J (2012) 0.92
Cardiac sodium-calcium exchange and efficient excitation-contraction coupling: implications for heart disease. Adv Exp Med Biol (2013) 0.90
Na/Ca exchange and contraction of the heart. J Mol Cell Cardiol (2013) 0.89
Na+ transport in cardiac myocytes; Implications for excitation-contraction coupling. IUBMB Life (2009) 0.89
Ca(2+)-activated Cl(-) current in rabbit sinoatrial node cells. J Physiol (2002) 0.88
Role of the Na(+)-Ca(2+) exchanger as an alternative trigger of CICR in mammalian cardiac myocytes. Biophys J (2002) 0.88
Phenylephrine acts via IP3-dependent intracellular NO release to stimulate L-type Ca2+ current in cat atrial myocytes. J Physiol (2005) 0.86
The Na+/Ca2+ exchanger-1 mediates left ventricular dysfunction in mice with chronic intermittent hypoxia. J Appl Physiol (1985) (2010) 0.85
Modeling effects of L-type ca(2+) current and na(+)-ca(2+) exchanger on ca(2+) trigger flux in rabbit myocytes with realistic T-tubule geometries. Front Physiol (2012) 0.85
Cardiac myocytes and local signaling in nano-domains. Prog Biophys Mol Biol (2011) 0.85
Cardiac electrophysiological dynamics from the cellular level to the organ level. Biomed Eng Comput Biol (2013) 0.82
Cardiac Na+-Ca2+ exchanger: dynamics of Ca2+-dependent activation and deactivation in intact myocytes. J Physiol (2013) 0.80
Sarcoplasmic Reticulum Structure and Functional Properties that Promote Long-Lasting Calcium Sparks. Biophys J (2016) 0.80
Calcium signalling in developing cardiomyocytes: implications for model systems and disease. J Physiol (2015) 0.78
Excitation contraction coupling in cardiac muscle: is there a purely voltage-dependent component? J Gen Physiol (2003) 0.78
Modeling Na(+)-Ca(2+) exchange in the heart: Allosteric activation, spatial localization, sparks and excitation-contraction coupling. J Mol Cell Cardiol (2016) 0.78
The mechanisms of sarcoplasmic reticulum Ca2+ release in toad pacemaker cells. J Physiol (2000) 0.77
Another trigger for the heartbeat. J Physiol (1998) 0.77
Regulation of Cardiomyocyte T-Tubular Structure: Opportunities for Therapy. Curr Heart Fail Rep (2017) 0.75
Total Ca handling in canine mild Ca overload failing heart. Heart Vessels (1999) 0.75
Isolated single coronary artery: a review of 50,000 consecutive coronary angiographies. Eur Heart J (1992) 4.59
Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med (1999) 4.53
Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med (2000) 4.19
Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation (1995) 3.38
Site-specific mutagenesis of Agrobacterium Ti plasmids and transfer of genes to plant cells. J Mol Appl Genet (1981) 3.31
Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry (2002) 2.87
Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. Lancet (1997) 2.80
Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation (1998) 2.32
Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation (1999) 2.16
Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA (1999) 2.08
Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation (1995) 2.08
One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. Circulation (1996) 2.03
Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev (2010) 1.99
[Prospective trial comparing Airtraq and Glidescope techniques for intubation of obese patients]. Ann Fr Anesth Reanim (2012) 1.98
IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry (2005) 1.98
Coronary artery fistulas in an adult population. Eur Heart J (1986) 1.92
Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol (1996) 1.91
Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol (2001) 1.89
Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunol (2003) 1.89
Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation (1999) 1.83
Association between -G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. Mol Psychiatry (2001) 1.78
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Enhanced Ca(2+) release and Na/Ca exchange activity in hypertrophied canine ventricular myocytes: potential link between contractile adaptation and arrhythmogenesis. Circulation (2000) 1.61
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. Eur Heart J (2004) 1.59
Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med (1984) 1.57
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart (2008) 1.54
Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation (1998) 1.52
Biological phenotypes underpin the physio-somatic symptoms of somatization, depression, and chronic fatigue syndrome. Acta Psychiatr Scand (2013) 1.51
Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J (1992) 1.50
High frame rate myocardial integrated backscatter. Does this change our understanding of this acoustic parameter? Eur J Echocardiogr (2000) 1.49
Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery. J Thorac Cardiovasc Surg (2006) 1.48
Effect of superoxide dismutase on infarct size and postischemic recovery of myocardial contractility and metabolism in dogs. J Am Coll Cardiol (1991) 1.47
Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy. Eur Heart J (2002) 1.43
Angiographic assessment of the infarct-related residual coronary stenosis after spontaneous or therapeutic thrombolysis. J Am Coll Cardiol (1990) 1.42
Evolution of early TIMI 2 flow after thrombolysis for acute myocardial infarction. GUSTO-1 Angiographic Investigators. Circulation (1996) 1.42
Recurrent ischemia after thrombolysis: importance of associated clinical findings. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary Arteries. J Am Coll Cardiol (1998) 1.42
Coronary reperfusion by thrombolysis and early beta-adrenergic blockade in acute experimental myocardial infarction. J Am Coll Cardiol (1989) 1.42
Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission? Eur Heart J (2003) 1.40
TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation (1999) 1.40
Paradoxical undersensing at a high sensitivity in dual chamber pacemakers. Pacing Clin Electrophysiol (2001) 1.40
Early and 3 months follow-up results in 22 adult patients undergoing percutaneous transvenous mitral valvuloplasty. Acta Cardiol (1990) 1.40
Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Eur Heart J (2000) 1.40
Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Ann Intern Med (1994) 1.40
Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol (2001) 1.39
Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-II. Eur Heart J (2002) 1.38
Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology (2001) 1.37
Heart rate variability and heart rate in healthy volunteers. Is the female autonomic nervous system cardioprotective? Eur Heart J (1998) 1.36
Present status of rescue coronary angioplasty: current polarization of opinion and randomized trials. J Am Coll Cardiol (1992) 1.34
Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. J Am Coll Cardiol (1993) 1.33
Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. Circulation (1998) 1.31
The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry (2012) 1.31
Indicators of immune activation in major depression. Psychiatry Res (1996) 1.30
Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network. J Am Coll Cardiol (2001) 1.27
Human complete androgen insensitivity with normal dihydrotestosterone receptor binding capacity in cultured genital skin fibroblasts: evidence for a qualitative abnormality of the receptor. J Clin Endocrinol Metab (1982) 1.24
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology (1995) 1.23
Increased serum albumin, gamma globulin, immunoglobulin IgG, and IgG2 and IgG4 in autism. Psychol Med (2002) 1.22
Semen parameters in a fertile versus subfertile population: a need for change in the interpretation of semen testing. Hum Reprod (1997) 1.22
T-type Ca2+ current as a trigger for Ca2+ release from the sarcoplasmic reticulum in guinea-pig ventricular myocytes. J Physiol (1998) 1.22
The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res (1998) 1.19
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol (2001) 1.16
Right atrial angiographic evaluation of the posterior isthmus: relevance for ablation of typical atrial flutter. Circulation (2000) 1.14
Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res (2001) 1.14
Prevalence and demographic features of childhood growth hormone deficiency in Belgium during the period 1986-2001. Eur J Endocrinol (2004) 1.13
Lowered serum n-3 polyunsaturated fatty acid (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered n-PUFAs are related to major depression. Life Sci (2003) 1.11
Imaging of gastrointestinal and abdominal tuberculosis. Eur Radiol (2004) 1.11
Search for a W' or techni-ρ decaying into WZ in pp Collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2012) 1.10
Seasonal and circadian rhythms in suicide in Cagliari, Italy. J Affect Disord (1999) 1.10
Search for new physics with same-sign isolated dilepton events with jets and missing transverse energy. Phys Rev Lett (2012) 1.09
Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation (1998) 1.09
Noninvasive quantification of the contractile reserve of stunned myocardium by ultrasonic strain rate and strain. Circulation (2001) 1.09
Search for supersymmetry at the LHC in events with jets and missing transverse energy. Phys Rev Lett (2011) 1.08
Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. J Am Coll Cardiol (1996) 1.07
Combination of serum markers related to several mechanisms in Alzheimer's disease. Neurobiol Aging (2003) 1.07
Search for stopped Gluinos in pp collisions at square root s=7 TeV. Phys Rev Lett (2011) 1.07
Multicenter study on reproducibility of sperm morphology assessments. Arch Androl (1998) 1.07
In humans, the seasonal variation in poly-unsaturated fatty acids is related to the seasonal variation in violent suicide and serotonergic markers of violent suicide. Prostaglandins Leukot Essent Fatty Acids (2004) 1.07
Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Circulation (1984) 1.06
Construct validity of the Beck Depression Inventory in a depressive population. J Affect Disord (1997) 1.05
Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur Neuropsychopharmacol (1995) 1.05
ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators. Am J Cardiol (2000) 1.05
Measurement of the Υ1S, Υ2S, and Υ3S polarizations in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2013) 1.05
Early increase in vegetative symptoms predicts IFN-alpha-induced cognitive-depressive changes. Psychol Med (2005) 1.04
Diastolic properties of the left ventricle in normal adults and in patients with third heart sounds. Circulation (1984) 1.04
Recombinant tissue-type plasminogen activator and immediate angioplasty in acute myocardial infarction. One-year follow-up. The European Cooperative Study Group. Circulation (1992) 1.03
The general concepts of an equivalence trial, applied to ASSENT-2, a large-scale mortality study comparing two fibrinolytic agents in acute myocardial infarction. Eur Heart J (2001) 1.01
Mutation screening in 18 Caucasian families suggest the existence of other MODY genes. Diabetologia (1998) 1.01
Trends in age at diagnosis of Turner syndrome. Arch Dis Child (2005) 1.01
Ventricular tachycardia as a complication of annular subvalvular ventricular aneurysm in a Caucasian woman. Eur Heart J (1987) 1.01
Nutritional regulation of insulin-like growth factor-I. Metabolism (1995) 1.00
Effects of serotonin and serotonergic agonists and antagonists on the production of interferon-gamma and interleukin-10. Neuropsychopharmacology (2000) 1.00
Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Pol J Pharmacol (2001) 0.99